Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:5:333-40.
Epub 2009 Jun 10.

Review of teriflunomide and its potential in the treatment of multiple sclerosis

Clemens Warnke  1 , Gerd Meyer zu Hörste, Hans-Peter Hartung, Olaf Stüve, Bernd C Kieseier
Affiliations

Review of teriflunomide and its potential in the treatment of multiple sclerosis

Clemens Warnke et al. Neuropsychiatr Dis Treat. 2009.

Abstract

In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

Keywords: immunosuppressant; multiple sclerosis; oral drugs; teriflunomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Efficacy of teriflunomide on the primary outcome measure in the phase II study.
See this image and copyright information in PMC

References

    1. Wiendl H, Toyka KV, Rieckmann P, et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255(10):1449–1463. - PubMed
    1. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007;356(25):2622–2629. - PubMed
    1. Rice GPA, Hartung H, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology. 2005;64(8):1336–1342. - PubMed
    1. Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. - PubMed
    1. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. - PubMed

LinkOut - more resources